These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 24330426

  • 1. Gender dependence of serum soluble Klotho in acromegaly.
    Sze L, Neidert MC, Bernays RL, Zwimpfer C, Wiesli P, Haile SR, Brändle M, Schmid C.
    Clin Endocrinol (Oxf); 2014 Jun; 80(6):869-73. PubMed ID: 24330426
    [Abstract] [Full Text] [Related]

  • 2. Excessively high soluble Klotho in patients with acromegaly.
    Sze L, Bernays RL, Zwimpfer C, Wiesli P, Brändle M, Schmid C.
    J Intern Med; 2012 Jul; 272(1):93-7. PubMed ID: 22452701
    [Abstract] [Full Text] [Related]

  • 3. Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values?
    Kohler S, Tschopp O, Sze L, Neidert M, Bernays RL, Spanaus KS, Wiesli P, Schmid C.
    Gen Comp Endocrinol; 2013 Jul 01; 188():282-7. PubMed ID: 23648743
    [Abstract] [Full Text] [Related]

  • 4. The relationship between serum GH and serum IGF-I in acromegaly is gender-specific.
    Parkinson C, Ryder WD, Trainer PJ, Sensus Acromegaly Study Group.
    J Clin Endocrinol Metab; 2001 Nov 01; 86(11):5240-4. PubMed ID: 11701684
    [Abstract] [Full Text] [Related]

  • 5. Chronic growth hormone excess is associated with increased aldosterone: a study in patients with acromegaly and in growth hormone transgenic mice.
    Bielohuby M, Roemmler J, Manolopoulou J, Johnsen I, Sawitzky M, Schopohl J, Reincke M, Wolf E, Hoeflich A, Bidlingmaier M.
    Exp Biol Med (Maywood); 2009 Aug 01; 234(8):1002-9. PubMed ID: 19491373
    [Abstract] [Full Text] [Related]

  • 6. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
    Jayasena CN, Comninos AN, Clarke H, Donaldson M, Meeran K, Dhillo WS.
    Clin Endocrinol (Oxf); 2011 Aug 01; 75(2):220-5. PubMed ID: 21521288
    [Abstract] [Full Text] [Related]

  • 7. GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment.
    Colao A, Terzolo M, Bondanelli M, Galderisi M, Vitale G, Reimondo G, Ambrosio MR, Pivonello R, Lombardi G, Angeli A, degli Uberti EC.
    Clin Endocrinol (Oxf); 2008 Oct 01; 69(4):613-20. PubMed ID: 18410555
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly.
    Parkinson C, Renehan AG, Ryder WD, O'Dwyer ST, Shalet SM, Trainer PJ.
    Clin Endocrinol (Oxf); 2002 Jul 01; 57(1):59-64. PubMed ID: 12100070
    [Abstract] [Full Text] [Related]

  • 10. Age and sex as predictors of biochemical activity in acromegaly: analysis of 1485 patients from the German Acromegaly Register.
    Petersenn S, Buchfelder M, Gerbert B, Franz H, Quabbe HJ, Schulte HM, Grussendorf M, Reincke M, Participants of the German Acromegaly Register.
    Clin Endocrinol (Oxf); 2009 Sep 01; 71(3):400-5. PubMed ID: 19226273
    [Abstract] [Full Text] [Related]

  • 11. In acromegaly, increased bone mineral density (BMD) is determined by GH-excess, gonadal function and gender.
    Zgliczynski W, Kochman M, Misiorowski W, Zdunowski P.
    Neuro Endocrinol Lett; 2007 Oct 01; 28(5):621-8. PubMed ID: 17984937
    [Abstract] [Full Text] [Related]

  • 12. Soluble Alpha Klotho in Acromegaly: Comparison With Traditional Markers of Disease Activity.
    Schweizer JROL, Schilbach K, Haenelt M, Giannetti AV, Bizzi MF, Soares BS, Paulino E, Schopohl J, Störmann S, Ribeiro-Oliveira A, Bidlingmaier M.
    J Clin Endocrinol Metab; 2021 Jul 13; 106(8):e2887-e2899. PubMed ID: 33864468
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS, Musolino NR, Salgado LR, Bronstein MD.
    Clin Endocrinol (Oxf); 2005 Aug 13; 63(2):168-75. PubMed ID: 16060910
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly.
    Sartorio A, Cattaneo M, Bucciarelli P, Bottasso B, Porretti S, Epaminonda P, Faglia G, Arosio M.
    Exp Clin Endocrinol Diabetes; 2000 Aug 13; 108(7):486-92. PubMed ID: 11083070
    [Abstract] [Full Text] [Related]

  • 18. Plasma levels of vascular endothelial growth factor in patients with acromegaly.
    Nagai Y, Ando H, Nohara E, Yamashita H, Takamura T, Kobayashi K.
    Horm Metab Res; 2000 Aug 13; 32(8):326-9. PubMed ID: 10983629
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.